SCHEMBL339160

SCHEMBL339160

BrCCSSCCBr

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1042991 0.82
SCHEMBL12861370 0.82
SCHEMBL31518697 0.73 TSHR (0.35)
SCHEMBL31188955 0.70 TSHR (0.33)
SCHEMBL7198099 0.68 TSHR (0.32)
SCHEMBL8727419 0.67 TDP1 (0.33)
SCHEMBL8315395 0.67
SCHEMBL12432228 0.64
SCHEMBL18636865 0.64
SCHEMBL2498768 0.64

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9944755-B2 Oxazoline polymer compositions and use thereof ANP TECHNOLOGIES, INC. (US) 2018-04-17 US claimed
US-20170066879-A1 Oxazoline Polymer Compositions and Use Thereof FULGENT GENETICS, INC. 2017-03-09 US claimed
US-20160024252-A1 Oxazoline Polymer Compositions and Use Thereof ANP TECHNOLOGIES, INC. (US) 2016-01-28 US claimed
WO-2013020005-A2 OXAZOLINE POLYMER COMPOSITIONS AND USE THEREOF ANP TECHNOLOGIES, INC. (US) 2013-02-07 WO claimed
EP-2075011-A2 Prodrugs Containing Bio-Cleavable Linkers Piramal Life Sciences Limited (IN) 2009-07-01 EP claimed
EP-3377504-B1 CYCLAM BASED COMPOUNDS, THEIR CONJUGATES, CO-ORDINATION COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, METHOD OF PREPARATION AND USE THEREOF UNIV KARLOVA (CZ) 2020-08-19 EP disclosed
US-10188605-B2 Nanoparticles and nanoparticle compositions IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2019-01-29 US disclosed
US-20180289821-A1 Oxazoline Polymer Compositions and Use Thereof ANP TECHNOLOGIES, INC. (US) 2018-10-11 US disclosed
EP-3377504-A1 CYCLAM BASED COMPOUNDS, THEIR CONJUGATES, CO-ORDINATION COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF, METHOD OF PREPARATION AND USE THEREOF Univerzita Karlova (CZ) 2018-09-26 EP disclosed
US-9944755-B2 Oxazoline polymer compositions and use thereof ANP TECHNOLOGIES, INC. (US) 2018-04-17 US disclosed
US-20170202971-A1 Oxazoline Polymer Compositions and Use Thereof ANP TECH INC (US) 2017-07-20 US disclosed
US-20170066879-A1 Oxazoline Polymer Compositions and Use Thereof FULGENT GENETICS, INC. 2017-03-09 US disclosed
US-20060080791-A1 Dyeing composition comprising at least one disulphide dye and method of dyeing human keratin fibers using this dye L'OREAL S.A. (FR) 2006-04-20 US disclosed
EP-1647580-A1 Dying composition comprising a particular disulfide dye and process of dying keratinous fibres with this dye. L'OREAL (FR) 2006-04-19 EP disclosed
WO-2006027711-A2 PRODRUGS AND CODRUGS CONTAINING BIO- CLEAVABLE DISULFIDE LINKERS NICHOLAS PIRAMAL INDIA LIMITED (IN) 2006-03-16 WO disclosed
US-20060046967-A1 Prodrugs containing novel bio-cleavable linkers Piramal Enterprises Limited (IN) 2006-03-02 US disclosed
US-6630496-B1 Antiinflammatory agents inhibit phospholipase 2, affecting both protaglandin and leukotriene production; indoles substituted in 2 position by 2,4-dioxo-thiazol-3-yl methylidene GENETICS INSTITUTE LLC 2003-10-07 US disclosed
EP-0251093-B1 Production of antibody catalysts IGEN INC (US) 1994-08-17 EP disclosed
US-4792446-A REACTION PRODUCT OF SUBSTRATE AND HAPTEN IGEN, INC. (US) 1988-12-20 US disclosed
EP-0251093-A2 Production of antibody catalysts IGEN, INC. (US) 1988-01-07 EP disclosed